New research being presented at this year’s European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Lisbon, Portugal, (23-26 April), has identified the third day of hospitalisation as a tipping point in the progression of disease among symptomatic patients admitted for COVID-19 pneumonia.
An overactive immune response to the SARS-CoV-2 virus can cause COVID-19 pneumonia with severe complications. Although medications such as corticosteroids can help control the inflammation associated with severe COVID-19 disease, there is significant variability in treatment response. Thus, there is an urgent need to identify biomarkers that are predictive of disease progression to help optimise treatment.
Dr Anthony Sophonsri and senior author Dr Annie Wong-Beringer, of the University of Southern California, Los Angeles, USA and colleagues studied patients hospitalised with COVID-19 pneumonia between March and October 2021.
The 90 patients (54% male) had a median age of 60 and were classified as having severe or non-severe COVID-19 as defined by the World Health Organisation.
Baseline characteristics were similar between groups except for higher rates of diabetes and chronic heart failure among the severe patients.
Blood samples were taken at days 1, 3, 5, and 7 of hospitalisation and levels of three host proteins that play vital roles in the COVID-19 immune response were measured using a novel point-of-need platform (MeMed) that yielded results within 15 minutes: interferon-γ induced protein 10(IP-10), C-reactive protein (CRP) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).
In general, TRAIL levels increased over time, while CRP and IP-10 fell in all patients.
On Day 1, there was no difference in levels of the proteins between the two groups.
But by Day 3, clear differences had emerged. TRAIL levels were lower (median 21 vs. 30 pg/mL) and IP-10 levels higher (median 713 vs. 328 pg/mL) in the severe group than the non-severe group. IP-10 levels also remained elevated until day 5 in the severe patients (median 560 vs. 212 pg/mL).
On Day 3, an IP-10 level of ≥ 570 pg/mL and a TRAIL level £25 pg/mL were indicators of progression to severe COVID-19 pneumonia.
Additionally, the severe group took longer to recover (12 days on average vs. 4 days), had a higher mortality rate (20% vs. 0%), and was eight times more likely to develop invasive secondary infections than the non-severe group.
The researchers say that the patterns in the host immune response could potentially be used to identify patients who are likely to become severely ill before they deteriorate.
They explain: “There are many patients who present to the emergency department only requiring minimal oxygen supplementation such as nasal cannula but soon progress to needing mechanical ventilation.
“Monitoring these immune proteins may help identify these patients sooner, allowing prompt escalation of care and more aggressive management of their overactive inflammatory response.”
Dr Sophonsri adds: “The observed patterns in the host immune response provide insight into the immunopathology of COVID-19, revealing a potential turning point in disease progression on Day 3 of admission and the utility of IP-10 and TRAIL as sensitive markers for disease progression to guide therapeutic intervention.”
To arrange an email with the study’s author, please email:
Dr Anthony Sophonsri, University of Southern California, Los Angeles, USA E) sophonsr@usc.edu
Alternative contact: Tony Kirby in the ECCMID Media Centre. T) +44 7834 385827 E) tony@tonykirby.comNotes to editors:
The authors declare no conflicts of interest. The study was partly-funded by MeMed Ltd.
This press release is based on oral presentation L0468 at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) Annual Meeting. The material has been peer reviewed by the congress selection committee. The research has been submitted to a journal but the full paper is not available at this stage.
For press release in Spanish click here
For press release in Portuguese click here
COI Statement
The authors declare no conflict of interest